Cite
HARVARD Citation
Zhou, M. et al. (2019). China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non‐small cell lung cancer after two lines of chemotherapy. Cancer communications. 39 (1), pp. 1-10. [Online].